Pfizer halts early trial of new RSV drug for babies
NCT ID NCT06102174
Summary
This study aimed to find a safe and effective dose of an experimental drug called sisunatovir for infants and young children (up to 5 years old) with serious RSV lung infections. It was a small, early-stage trial that compared the drug to a placebo to check for side effects and how the body processes the medicine. The study was terminated by the sponsor and did not proceed to later phases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kaiser Permanente
Los Angeles, California, 90027, United States
-
Kaiser Permanente Los Angeles Medical center
Los Angeles, California, 90027, United States
-
Kojunkai Daido Hospital
Nagoya, Aichi-ken, 457-8511, Japan
-
Monti Clinical Research Centre
Mdantsane, Eastern Cape, 5219, South Africa
-
Nintenkai Kagoshima Children's Hospital
Hioki, Kagoshima-ken, 899-2503, Japan
-
Osaka City General Hospital
Osaka, 534-0021, Japan
-
University of Witwatersrand (WITS) - Vaccines and Infectious Diseases Analytics (VIDA)
Johannesburg, Gauteng, 2013, South Africa
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Yamanashi Prefectural Central Hospital
Kofu, Yamanashi, 400-8506, Japan
Conditions
Explore the condition pages connected to this study.